{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-25-000012","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.721823+00:00","generated_at":"2026-05-23T01:39:50.798196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AptarGroup Q1 2025: sales down 3% to $887M, adjusted EPS $1.20, guides Q2 EPS $1.56-$1.64","bullets":["Reported sales down 3% to $887M; net income down 5% to $79M; adjusted EPS $1.20 vs $1.22 prior year.","Pharma core sales +3% on drug delivery systems; Beauty core -3% on lower fragrance; Closures core -2%.","Adjusted EBITDA $183M (+3%); margin 20.7% (+120 bps) driven by pharma royalties.","Q2 2025 adjusted EPS guidance $1.56-$1.64; effective tax rate 19%-21% vs 24% adjusted prior year.","Repurchased 548k shares for $80M; quarterly dividend $0.45/share payable May 22, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-25-000012","json":"https://secwatch.observer/filing/0000896622-25-000012.json","markdown":"https://secwatch.observer/filing/0000896622-25-000012.md","text":"https://secwatch.observer/filing/0000896622-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000012/0000896622-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000012/atr-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:39:50.798196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}